Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating BxC-I17e for moderate to severe atopic dermatitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• BxC-I17e

Snippet

Sponsor: Brexogen Inc. | Conditions: Atopic Dermatitis | Phase 1 | Status: WITHDRAWN